We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+12.64%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$10.5B
AUM Growth
+$891M
Cap. Flow
+$177M
Cap. Flow %
1.69%
Top 10 Hldgs %
36.27%
Holding
147
New
14
Increased
53
Reduced
21
Closed
16

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$98.5M
2
SIEN
Sientra, Inc.
SIEN
+$54.3M
3
GILD icon
Gilead Sciences
GILD
+$50.4M
4
MGLN
Magellan Health Services, Inc.
MGLN
+$47.6M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$42.9M

Top Sells

Rank Stock Value
1
CFN
CAREFUSION CORPORATION
CFN
+$215M
2
A icon
Agilent Technologies
A
+$79M
3
ARWR icon
Arrowhead Research
ARWR
+$76.5M
4
STJ
St Jude Medical
STJ
+$54.8M
5
QGENF
QIAGEN NV
QGENF
+$38.7M

Sector Composition

Rank Sector Weight
1 Healthcare 88.46%
2 Miscellaneous 11.3%
3 Technology 0.16%
4 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
126
Eli Lilly
LLY
$1.02T
– –
-112,000
Closed -$7.26M
PBYI icon
127
CALL
Puma Biotechnology
PBYI
$483M
– –
-60,000
Closed -$14.3M
VTRS icon
128
Viatris
VTRS
$18.9B
– –
-169,100
Closed -$7.69M
VIRX
129
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-1,667
Closed -$2.5M
VIRX
130
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-5,714
Closed -$8.57M
CSII
131
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-170,000
Closed -$4.02M
GWPH
132
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-221,000
Closed -$17.9M
FPRX
133
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-1,075,400
Closed -$12.6M
SLXP
134
CALL
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-200,000
Closed -$31.2M
CFN
135
DELISTED
CAREFUSION CORPORATION
CFN
– –
-4,756,000
Closed -$215M
DRTX
136
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
– –
-1,785,714
Closed -$22.6M
AMBI
137
DELISTED
Ambit Biosciences Corp
AMBI
– –
-1,490,769
Closed -$23M
QGENF
138
DELISTED
QIAGEN NV
QGENF
– –
-1,700,000
Closed -$38.7M
2 3 4 5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2014 Portfolio in Review

As of Q4 2014, OrbiMed held 147 positions worth $10.5B, up 9.3% from $9.57B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed's Q4 2014 filing shows 14 new, 53 increased, 21 reduced and 16 closed positions. Its largest new stake was Sientra, Inc.: 318,531 shares worth $53.5M. The largest sale was CAREFUSION CORPORATION, an estimated $215M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Technology.

  • OrbiMed's largest Q4 2014 buy was Sientra, Inc.: 318,531 shares worth $53.5M.
  • OrbiMed added most to Biogen in Q4 2014, an estimated $98.5M increase.
  • OrbiMed's biggest Q4 2014 reduction was Agilent Technologies, cutting an estimated $79M.
  • OrbiMed fully exited CAREFUSION CORPORATION in Q4 2014, selling an estimated $215M.
  • OrbiMed's ten largest holdings make up 36% of its $10.5B portfolio in Q4 2014.
  • OrbiMed opened 14 new positions and closed 16 in Q4 2014.
  • OrbiMed's portfolio value rose 9.3% quarter-over-quarter to $10.5B.

Based on OrbiMed's 13F filing for Q4 2014, filed 13 Feb 2015.